During biologics discovery the ability to evaluate antigen-antibody interactions via multiplexed binding assays at high throughput provides more comprehensive information in the primary screening phase. Identifying hits by simultaneous evaluation of specificity and cross-reactivity builds confidence in potential hits, and increases the likelihood that candidate molecules will successfully proceed through downstream steps in the discovery and development process.
This webinar features two user talks that demonstrate how the Intellicyt iQue Screener platform enhanced productivity in their biologics discovery workflow. Details are provided below:
- In this presentation Yana Wang, Ph.D., from Takeda Pharmaceuticals will highlight they multiplex multiple cell lines of interest in one well to simultaneously quantitate on-target activity, cross-reactivity and non-specific activity along with measurement of antibody concentration using, the Intellicyt iQue Screener PLUS platform. This ability to measure multiple parameters coupled with the platform’s speed and increased accuracy provides gains in productivity and helps accelerate antibody discovery.
- In this presentation, Robert Ford, Ph.D., from Avacta Life Sciences will provide an overview of novel Anti-idiotpyic Affimer® reagents and their importance in the bioanalysis of therapeutic antibody drug candidates and demonstrate how these Affimer® reagents are identified using the Intellicyt iQue Screener platform by incorporating cross-reactivity profiling against similar antibody drug candidates into the primary screening phase of the discovery process.
Yana Wang, Ph.D.
Yana is currently working in Lead Discovery group at Oncology Drug Discovery Unit, Takeda Pharmaceuticals. She has extensive experience in cell based assay development and screening for both small molecules and biologics, including high content imaging, reporter gene assay, cell viability/toxicity assay etc. She is specialized in integrating laboratory automation for high throughput assay development. Before joining Takeda in 2011, she obtained her Ph. D. in Chemical Engineering from Massachusetts Institute of Technology.
Robert Ford, Ph.D.
Avacta Life Sciences
Dr. Robert Ford works as a Senior Scientist in the validation team at Avacta Life Sciences. His expertise is used to generate data using Affimer technology in customer, internal and collaborative projects. Rob has academic background in Biochemistry and Molecular Biology, his PhD involved investigating (+)ssRNA icosahedral virus assembly and dis-assembly mechanisms in model viral systems